Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study-Reference-Cited by-同舟云学术

Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study

Published:2019-12-01 Issue:12 Volume:29 Page:1811-1819
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Lee Eun Kyung¹,Kim Seok-Mo²,Kim Bo Hyun³,Kim Min Joo⁴⁵,Lim Dong-Jun⁶,Kim Min-Hee⁶,Shin Dong Yeob⁷,Kang Ho-Cheol⁸,Ahn Byeong-Cheol⁹,Kim Sun Wook¹⁰,Ahn Hwa Young¹¹,Park Young Joo⁴

Affiliation:

1. Center for Thyroid Cancer, National Cancer Center, Goyang, Korea.

2. Department of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

3. Department of Internal Medicine, Pusan National University Hospital, Biomedical Research Institute, Pusan National University School of Medicine, Busan, Korea.

4. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

5. Department of Internal Medicine, Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea.

6. Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.

7. Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

8. Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.

9. Department of Nuclear Medicine, School Medicine, Kyungpook National University, Daegu, Korea.

10. Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

11. Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2019.0022

Reference29 articles.

1. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?

2. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial

3. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions

4. Treatment of refractory thyroid cancer

5. Refractory thyroid carcinoma: which systemic treatment to use?

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can 99Tcm-3PRGD2(ανβ3) and 18F-FDG dual-tracer molecular imaging change the therapeutic strategy for progressive refractory differentiated thyroid cancer: Case report;Medicine;2023-02-03

2. The osteopontin expression and microvascular density in thyroid cancer, comparison of CT and ultrasound in diagnosis of thyroid cancer and correlations of CT features and thyroid cancer;Minerva Endocrinology;2023-01

3. Daily Management of Patients on Multikinase Inhibitors’ Treatment;Frontiers in Oncology;2022-07-04

4. Recent Improvements in the Treatment of High-Risk Thyroid Cancer;Korean Society for Head and Neck Oncology;2022-05-30

5. New approaches for patients with advanced radioiodine-refractory thyroid cancer;World Journal of Clinical Oncology;2022-01-24